|
Name |
Ergosta-6,22-diene-3beta,5alpha,8alpha-triol
|
Molecular Formula | C28H46O3 | |
IUPAC Name* |
(3S,5S,8S,9R,10R,13R,14R,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3,5,8-triol
|
|
SMILES |
C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@@]2(C=C[C@@]4([C@@]3(CC[C@@H](C4)O)C)O)O)C
|
|
InChI |
InChI=1S/C28H46O3/c1-18(2)19(3)7-8-20(4)22-9-10-23-25(22,5)13-12-24-26(6)14-11-21(29)17-27(26,30)15-16-28(23,24)31/h7-8,15-16,18-24,29-31H,9-14,17H2,1-6H3/b8-7+/t19-,20+,21-,22+,23+,24+,25+,26+,27+,28-/m0/s1
|
|
InChIKey |
UPJVQRZPXLZUET-KGHQQZOUSA-N
|
|
Synonyms |
CHEMBL464314; Ergosta-6,22-diene-3beta,5alpha,8alpha-triol; (8S,22E)-5alpha-Ergosta-6,22-diene-3beta,5,8alpha-triol
|
|
CAS | NA | |
PubChem CID | 15251535 | |
ChEMBL ID | CHEMBL464314 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 430.7 | ALogp: | 5.7 |
HBD: | 3 | HBA: | 3 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 60.7 | Aromatic Rings: | 4 |
Heavy Atoms: | 31 | QED Weighted: | 0.502 |
Caco-2 Permeability: | -4.806 | MDCK Permeability: | 0.00001960 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.973 |
Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.825 |
30% Bioavailability (F30%): | 0.275 |
Blood-Brain-Barrier Penetration (BBB): | 0.254 | Plasma Protein Binding (PPB): | 88.86% |
Volume Distribution (VD): | 0.991 | Fu: | 1.46% |
CYP1A2-inhibitor: | 0.023 | CYP1A2-substrate: | 0.855 |
CYP2C19-inhibitor: | 0.05 | CYP2C19-substrate: | 0.857 |
CYP2C9-inhibitor: | 0.18 | CYP2C9-substrate: | 0.046 |
CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.062 |
CYP3A4-inhibitor: | 0.85 | CYP3A4-substrate: | 0.899 |
Clearance (CL): | 2.068 | Half-life (T1/2): | 0.131 |
hERG Blockers: | 0.279 | Human Hepatotoxicity (H-HT): | 0.229 |
Drug-inuced Liver Injury (DILI): | 0.007 | AMES Toxicity: | 0.001 |
Rat Oral Acute Toxicity: | 0.399 | Maximum Recommended Daily Dose: | 0.984 |
Skin Sensitization: | 0.154 | Carcinogencity: | 0.003 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.048 |
Respiratory Toxicity: | 0.969 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004740 | 0.700 | D0G8OC | 0.439 | ||||
ENC005015 | 0.700 | D0G5CF | 0.407 | ||||
ENC001640 | 0.700 | D06JPB | 0.402 | ||||
ENC005013 | 0.700 | D0Y7LD | 0.347 | ||||
ENC005779 | 0.700 | D0N1TP | 0.328 | ||||
ENC005438 | 0.615 | D01QUS | 0.305 | ||||
ENC001984 | 0.615 | D03ZTE | 0.288 | ||||
ENC004757 | 0.615 | D0G3SH | 0.288 | ||||
ENC004804 | 0.615 | D08SVH | 0.287 | ||||
ENC006034 | 0.575 | D0M4WA | 0.287 |